Sulfasalazine for liver fibrosis and cirrhosis
Part of Digestive system clinical trials.
This study tests if sulfasalazine, a medicine already used for other conditions, is safe and helpful for people with liver scarring (fibrosis or cirrhosis). It is for patients with cirrhosis caused by certain liver diseases, like PBC, hepatitis B, hepatitis C, or alcohol use.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 70 years old, with a body mass index (BMI) between 18 and 32.
- You have been diagnosed with cirrhosis caused by primary biliary cholangitis (PBC), hepatitis B, hepatitis C, or alcohol.
- If you have PBC, you must have tried UDCA for at least 12 months and it didn't work well enough.
- You cannot be allergic to sulfa drugs, sulfasalazine, or salicylates (like aspirin).
- You must not have liver cancer, another active cancer, or a serious condition affecting your heart, lungs, kidneys, or gut.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether fenofibrate (a cholesterol medicine) can improve outcomes in people with primary biliary cholangitis (PBC) who already take ursodeoxycholic acid (UDCA) but still have abnormal liver blood tests. It specifically looks at people with “compensated” (stable) cirrhosis—meaning the liver disease is present but not causing severe complications right now.
This trial tests a medicine called seladelpar for people with primary biliary cholangitis (PBC) and cirrhosis, a form of liver scarring. The goal is to see if it can help improve liver health and reduce symptoms.
This study tests a new drug called saroglitazar to see if it can improve long-term outcomes in people with primary biliary cholangitis (PBC) who have cirrhosis. It may be an option if you are already on UDCA or cannot take it, and if your liver function tests meet certain levels.
This trial tests adding prednisone (a steroid) to ursodeoxycholic acid (a bile acid medicine) for people with primary biliary cholangitis who have a specific type of liver inflammation. The goal is to see if the combination works better at controlling the disease than standard care.
This trial tests whether the blood thinner apixaban can help prevent early-stage cirrhosis from worsening. You may be eligible if you have compensated (stable) cirrhosis due to alcohol and have signs of portal hypertension.
This study tests whether a new drug called AZD2389 is safe and well-tolerated in adults with steatotic liver disease (fatty liver) that has progressed to advanced scarring. The trial aims to see if this drug might help slow or improve liver damage in people with this condition.
Hear when a new Cirrhosis, Liver trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.